Retatrutide 40
once weekly · 133 µg per click · 300 clicks per pen
2 mg · 15 clicks
Published titration protocols open at the lowest full dose so tolerance can be mapped before capacity is raised. The first four weeks are a tolerance window, not a results window, the reference schedule holds here deliberately.
4 mg · 30 clicks
Once the on-ramp is comfortable, the reference schedule doubles the click count. This is the band where the phase-2 curve begins to move in the literature. If tolerance markers linger, the printed card holds the lower dose for another fortnight.
8 mg · 60 clicks
The full reference dose, and the ceiling on this pen. It is reached by titration, never started cold. From week eight the variable that matters is consistency: same day, same clicks, held long enough for the data to accrue.
Retatrutide 40 Pen Specifications and Unit Conversion | Veyvora
The Veyvora Retatrutide 40 pen is specified as a 3 mL multi-dose pen containing 40 mg of retatrutide, delivering 133 µg per click across 300 clicks, according to Veyvora’s 2026 product specification. The table below converts the three reference quantities most commonly needed in laboratory settings.
| Reference quantity | Clicks (at 133 µg/click) | Volume equivalent |
|---|---|---|
| 2 mg | 15 clicks | 0.150 mL |
| 4 mg | 30 clicks | 0.301 mL |
| 8 mg | 60 clicks | 0.602 mL |
Research reference only. These figures are derived from Veyvora’s stated 133 µg-per-click specification and are not instructions for human use.
This retatrutide 40 dosage guide presents 2 mg, 4 mg and 8 mg as laboratory reference points for unit conversion and batch verification. All three quantities are research reference values only; none constitutes a clinical recommendation. Retatrutide remains unlicensed in the United Kingdom as of 2026, with no MHRA marketing authorisation [4]. The sections below explain how to verify the click arithmetic against the label, reconcile batch documentation, and apply appropriate measurement error checks within a strictly research-use-only framework.
Retatrutide 40 Pen Specifications and Unit Conversion: Technical Scope
The Veyvora Retatrutide 40 pen is a label-derived laboratory specification reference, not a dosing guide. Its stated parameters, 40 mg total peptide content, 3 mL fill volume, 300 clicks and 133 µg per click, are measurable quantities for unit conversion and batch verification within a research-use-only framework.
| Parameter | Stated value | Derivation basis |
|---|---|---|
| Total retatrutide content | 40 mg | Label declaration |
| Fill volume | 3 mL | Label declaration |
| Nominal concentration | 13.3 mg/mL | 40 mg ÷ 3 mL |
| Clicks per full pen | 300 | Manufacturer specification (2026) |
| Peptide mass per click | 133 µg | 40 mg ÷ 300 clicks |
Research reference only. Values are derived from Veyvora’s 2026 stated specification and are not instructions for human use.
All downstream arithmetic, including retatrutide 2 mg, retatrutide 4 mg and retatrutide 8 mg reference quantities, must trace back to these four declared parameters. The Retatrutide 40 product specification provides the primary product identity and format; the retatrutide research profile covers receptor pharmacology separately. Concentration expressed as mg/mL is the standard unit used in verified reference materials for retatrutide products [3].
Verified Pen Specifications
Veyvora’s 2026 product specification declares four parameters for the Retatrutide 40 pen: 40 mg total retatrutide content, 3 mL fill volume, 300 clicks per full pen, and 133 µg peptide mass per click.
| Parameter | Stated value | Source basis |
|---|---|---|
| Total retatrutide content | 40 mg | Veyvora 2026 label declaration |
| Fill volume | 3 mL | Veyvora 2026 label declaration |
| Nominal concentration | 13.3 mg/mL | 40 mg ÷ 3 mL |
| Clicks per full pen | 300 | Veyvora 2026 manufacturer specification |
| Peptide mass per click | 133 µg | 40 mg ÷ 300 clicks |
Research reference only. Not instructions for human use.
The 13.3 mg/mL nominal concentration follows directly from Veyvora’s declared 40 mg in 3 mL fill (40 mg ÷ 3 mL). Any parameter not confirmed by a current label or batch certificate should be flagged for operator verification before use in a laboratory protocol.
Veyvora states that each batch is verified independently by Asterion Analytics, then again by Veyvora’s own internal testing, using HPLC, mass spectrometry and endotoxin assay, with a published batch certificate of analysis available for verification before first use. Researchers should verify a batch against its COA before incorporating any material into a protocol, and should consult what HPLC purity does and does not prove to understand the analytical limits behind any purity figure.
Unit-Conversion Method
For the Veyvora Retatrutide 40 pen, all quantity calculations follow a single relationship: volume (mL) = target mass (mg) ÷ concentration (mg/mL), with click count derived by dividing the resulting volume by the volume delivered per click [3].
The pen’s stated concentration of 13.3 mg/mL (40 mg ÷ 3 mL) and 133 µg per click allow the following reference conversions to be verified arithmetically [3]:
| Target mass | Calculation | Volume (mL) | Clicks (at 133 µg/click) |
|---|---|---|---|
| 2 mg | 2 ÷ 13.3 | 0.150 mL | 15 |
| 4 mg | 4 ÷ 13.3 | 0.301 mL | 30 |
| 8 mg | 8 ÷ 13.3 | 0.602 mL | 60 |
Research reference only. Not instructions for human use.
These figures are derived solely from Veyvora’s stated pen parameters. Any deviation between the arithmetic result and the value on a batch certificate should be flagged for operator verification before the material enters a protocol.
Syringe-Based Cross-Check
Where a U-100 insulin syringe is used alongside a reconstituted vial rather than a pen, the standard relationship is 1 mL = 100 syringe units, so units to draw = (target mass in mg ÷ concentration in mg/mL) × 100 [3]. At 13.3 mg/mL, each syringe unit corresponds to approximately 0.133 mg (133 µg), consistent with the per-click figure above. This cross-check confirms internal consistency between pen-click and syringe-unit representations of the same concentration.
All conversion outputs should be treated as calculated reference values. Operators must confirm the concentration against the batch certificate of analysis before applying any figure to a laboratory protocol. For guidance on maintaining concentration integrity after opening, see storage and stability guidance.
Label and Batch-Document Reconciliation
Reconciliation confirms that every value entering a calculation is traceable to the same physical batch. For any retatrutide 40 pen, four declared fields must agree across the outer carton, the primary label and the certificate of analysis: total peptide mass (mg), fill volume (mL), concentration (mg/mL) and presentation format (prefilled pen vs reconstituted vial) [1][3].
Four-Field Reconciliation Checklist
| Field | Where to verify | Expected value (Retatrutide 40 pen) |
|---|---|---|
| Total peptide mass | Primary label + CoA assay result | 40 mg (confirm % of label claim ≥ specification) |
| Fill volume | Primary label + CoA fill-volume entry | 3 mL |
| Concentration | Calculated: 40 mg ÷ 3.0 mL | 13.3 mg/mL |
| Per-click delivery | Mechanical calibration record | 133 µg/click |
Where a supplier provides a reconstitution chart or calculator, treat such tools as secondary aids: cross-check them against the primary label and batch certificate rather than treating them as proof of concentration. Any arithmetic discrepancy between the calculated concentration and the assay result on the certificate should be flagged and resolved before the material enters a protocol.
For the full declared specification of the Retatrutide 40 pen, see the Retatrutide 40 product specification.
Measurement Limits and Error Checks
Three categories of error affect retatrutide pen calculations: rounding at intermediate steps, unit mismatches between device types, and values transferred from a different product configuration without adjustment.
Rounding
Per-click concentration is a derived figure. Dividing 40 mg by 300 clicks yields 0.1333… mg per click; rounding to 133 µg introduces a cumulative shortfall of approximately 0.1 mg across a full pen. Laboratories should carry at least four significant figures through intermediate calculations and round only the final reported value.
Unit Mismatches
Peptide-protocol references for reconstituted vials commonly express concentration as mg/mL and translate volume into U-100 syringe units, where 1 unit equals 0.01 mL [3]. A prefilled pen delivering a fixed µg per click uses an entirely different measurement basis. Applying a syringe-unit table to a click-count pen, or vice versa, produces systematic error. Confirm which delivery mechanism applies before selecting a conversion table.
Values Transferred from Another Product
The Veyvora Retatrutide 40 pen’s nominal concentration of 13.3 mg/mL is derived solely from its declared 40 mg in 3 mL fill (40 ÷ 3) [1]. Arithmetic derived from a differently-sized pen or reconstituted vial, including per-click mg figures, must not be applied to the 40 mg pen without independent confirmation from that pen’s batch certificate. Verify a batch against its COA to confirm the lot-specific assay result matches the declared concentration before any laboratory calculation proceeds.
HPLC purity percentage, where reported, confirms peptide identity and relative purity but does not independently validate fill volume or per-click delivery accuracy [3]. Gravimetric or volumetric testing of total delivered volume against the label remains a separate, necessary check. For the scope of what HPLC results do and do not establish, see what HPLC purity does and does not prove.
Research-Use-Only Limitations
Retatrutide is currently unlicensed in the United Kingdom, with no MHRA marketing authorisation as of 2026, and its legality for any use outside authorised clinical trials is under active regulatory scrutiny [4].
No Regulatory Framework for Quality Assurance
The MHRA states that retatrutide remains in clinical development and has no UK marketing authorisation; it is not authorised for weight-loss or any other human use, and products marketed to the public claiming to contain it are unlicensed medicines [4]. Veyvora supplies retatrutide for in-vitro laboratory research use only. Because retatrutide sold as a research compound carries no regulator-issued Summary of Product Characteristics, no MHRA factory inspection applies, and no Yellow Card route exists for harm reporting. Responsibility for identity, purity, concentration and stability verification rests entirely with the research user and any independent accredited laboratory they engage.
Scope Boundary for This Reference
All click counts, per-click masses and concentration figures on this page are laboratory measurement parameters only. None of the values, including retatrutide 2 mg, retatrutide 4 mg and retatrutide 8 mg reference quantities, constitute dosing instructions, titration protocols or clinical guidance. Applying these figures to human administration falls outside the verified scope of this page and outside the legal framework for unlicensed compounds in the United Kingdom [2][4].
Before handling any batch, consult the storage and stability guidance for documented 2–8 °C requirements, then verify a batch against its COA to confirm the lot-specific assay result matches the declared concentration.
Sources
[1] Retatrutide 40 mg Pen | Veyvora, veyvora.com, https://veyvora.com/peptides/retatrutide-40 [2] The Human Medicines Regulations 2012, legislation.gov.uk, https://www.legislation.gov.uk/uksi/2012/1916 [3] Retatrutide 40 pen specification, Veyvora, veyvora.com, https://veyvora.com/dosing/retatrutide-40 [4] Medicines and Healthcare products Regulatory Agency (MHRA) products register, gov.uk, https://products.mhra.gov.uk/
